ECONOMYNEXT – China’s Sinopharm vaccine triggers an immune response for Coronavirus (seroconversion) in 95 percent of the recipients with higher 98 percent seen in younger persons, a study in Sri Lanka has found.
The study involved 282 individuals who were not infected at the time of vaccination and 41 who have had the disease already.
After 6 weeks (two weeks after the second dose) 95 percent were seropositive.
“The seroconversion rates were highest in the 20 to 39 age group (98.88%) at 6 weeks (2 weeks afer obtaining the 2dn does)… the study by Sri Lanka’s Sri Jayewardenepura University said.
It was 93 percent in the above 60 year olds. The third group was between 41 to 60 years.
Neelika Malavige and Chandima Jeewandara at the university has led Coronavirus research in Sri Lanka.
Our data on the Sinopharm vaccine immunogenecity. @ChinaEmbSL @Chinamission2un @covidexpertlist @chandi2012
Antibody and T cell responses to Sinopharm/BBIBP-CorV in naive and previously infected individuals in Sri Lanka https://t.co/E5Zyr0Ny7C
— Neelika Malavige (@GMalavige) July 19, 2021
The researchers studied ACE2 receptor blocking antibodies (81.25 percent had after 6 weeks) T cell and B cell responses.
“..[T]he vaccine appears to induce similar levels of ACE2 receptor blocking antibodies and RBD binding antibodies to B.1.617.2 as seen following natural infection, ” the researchers said.
“However, seroconversion rates and immunogenicity appear to be lower in older individuals. The vaccine induced robust T cell responses and memory B cell responses in the vaccinees although the
magnitude of responses were less than those observed with some other vaccines.”